These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 28110381)

  • 21. Minimal residual disease in acute myeloid leukemia--current status and future perspectives.
    Kayser S; Walter RB; Stock W; Schlenk RF
    Curr Hematol Malig Rep; 2015 Jun; 10(2):132-44. PubMed ID: 25994952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Sun Y; Zhu G; Zhong H
    Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beyond morphology: minimal residual disease detection in acute myeloid leukemia.
    DiNardo CD; Luger SM
    Curr Opin Hematol; 2012 Mar; 19(2):82-8. PubMed ID: 22314322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
    Stone RM
    Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Brooimans RA; van der Velden VHJ; Boeckx N; Slomp J; Preijers F; Te Marvelde JG; Van NM; Heijs A; Huys E; van der Holt B; de Greef GE; Kelder A; Schuurhuis GJ
    Leuk Res; 2019 Jan; 76():39-47. PubMed ID: 30553189
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them.
    Li SQ; Chen M; Huang XY; Wang H; Chang YJ
    Expert Rev Hematol; 2023; 16(12):981-990. PubMed ID: 37978882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.
    Buldini B; Rizzati F; Masetti R; Fagioli F; Menna G; Micalizzi C; Putti MC; Rizzari C; Santoro N; Zecca M; Disarò S; Rondelli R; Merli P; Pigazzi M; Pession A; Locatelli F; Basso G
    Br J Haematol; 2017 Apr; 177(1):116-126. PubMed ID: 28240765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.
    Wood BL
    Curr Protoc Cytom; 2020 Jun; 93(1):e73. PubMed ID: 32311834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].
    Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges.
    Gaipa G; Buracchi C; Biondi A
    Expert Rev Mol Diagn; 2018 Sep; 18(9):775-787. PubMed ID: 30047795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts.
    Chea M; Rigolot L; Canali A; Vergez F
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
    Eckel AM; Cherian S; Miller V; Soma L
    Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
    Yang F; Anekpuritanang T; Press RD
    Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAGIC-DR: An interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis.
    Shopsowitz K; Lofroth J; Chan G; Kim J; Rana M; Brinkman R; Weng A; Medvedev N; Wang X
    Cytometry B Clin Cytom; 2024 Jul; 106(4):239-251. PubMed ID: 38415807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurable residual disease testing for personalized treatment of acute myeloid leukemia.
    Ehinger M; Pettersson L
    APMIS; 2019 May; 127(5):337-351. PubMed ID: 30919505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions.
    DiNardo C; Lachowiez C
    Curr Hematol Malig Rep; 2019 Oct; 14(5):386-394. PubMed ID: 31350639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.